[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054192":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":22,"responsibleParty":38,"collaborators":10,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":54,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Haseki Training and Research Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Neonates Receiving Phototherapy",null,"This cohort includes neonates admitted to the NICU and treated with phototherapy for neonatal hyperbilirubinemia according to current institutional protocols and guideline-based phototherapy thresholds. Both standard and intensive phototherapy modalities may be used depending on bilirubin levels, gestational age, and neurotoxicity risk factors.\n\nPhototherapy is administered using Astek phototherapy devices and\u002For tunnel phototherapy systems, either as single-device or double-device therapy. Irradiance intensity may be adjusted according to clinical severity. Phototherapy is applied continuously except during feeding and routine care intervals.\n\nSerum bilirubin levels are monitored during and after phototherapy according to unit protocol. Rebound bilirubin measurements are routinely obtained after discontinuation of phototherapy, and additional measurements are performed in neonates considered at increased risk for rebound hyperbilirubinemia. Clinical, labo",[13],{"name":14,"affiliation":15,"role":16},"Dilek Kurnaz, M.D","Health Sciences University, Haseki Training and Research Hospital","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","+905556119280","drdilekkurnaz@gmail.com",[23],{"facility":24,"status":10,"city":25,"state":26,"zip":27,"country":28,"countryCode":10,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"University of Health Sciences, Haseki Training and Research Hospital","Istanbul","Sultangazi","34265","Turkey (Türkiye)",{"type":30,"coordinates":31},"Point",[32,33],28.94966,41.01384,{"lat":33,"lon":32},[36],{"name":14,"role":19,"phone":37,"phoneExt":10,"email":21},"05556119280",{"type":16,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Berker Okay","M.D","100054192","predictors-of-rebound-hyperbilirubinemia-study-100054192",false,"NCT07694635","Predictors of Rebound Hyperbilirubinemia Study","Predictors of Rebound Hyperbilirubinemia After Phototherapy in Neonates","Inclusion Criteria:\n\n* Neonates admitted to the NICU with neonatal hyperbilirubinemia\n* Gestational age ≥35 weeks\n* Requirement for phototherapy according to institutional protocol and current guideline-based phototherapy thresholds\n* Receipt of standard and\u002For intensive phototherapy\n* Availability of bilirubin measurements before, during, and after phototherapy\n* Availability of rebound bilirubin measurement within 48 hours after phototherapy discontinuation\n* Written informed consent obtained from parents or legal guardians, if required by the ethics committee\n\nExclusion Criteria:\n\n* Major congenital anomalies\n* Conjugated hyperbilirubinemia\n* Neonates requiring exchange transfusion before completion of initial phototherapy\n* Severe perinatal asphyxia\n* Proven or suspected inborn errors of metabolism affecting bilirubin metabolism\n* Significant congenital liver disease\n* Neonates transferred to another center before completion of rebound bilirubin follow-up\n* Missing or incomplete clinical or laboratory data\n* Absence of rebound bilirubin measurement within 48 hours after phototherapy discontinuation\n* Parents or legal guardians declining participation, if consent is required","ALL","2 Hours","28 Days",{"count":52,"type":53},300,"ESTIMATED","2 Days","OBSERVATIONAL","\\## Brief Summary\n\nNeonatal hyperbilirubinemia is one of the most common causes of neonatal hospitalization and phototherapy treatment. Although phototherapy is highly effective, rebound hyperbilirubinemia following discontinuation of phototherapy may occur in some infants and may require repeat treatment. Early identification of neonates at risk for clinically significant rebound hyperbilirubinemia could help optimize discharge timing and reduce unnecessary hospital stay and repeat bilirubin testing.\n\nThis prospective observational study aims to evaluate the predictors of rebound hyperbilirubinemia after phototherapy discontinuation in neonates admitted to the NICU. Particular focus will be placed on the role of delta total serum bilirubin (ΔTSB), defined as the difference between the phototherapy threshold and the measured bilirubin level at the time of phototherapy discontinuation. Clinical, demographic, laboratory, hemolytic, feeding-related, and phototherapy-related variables will also be analyzed.\n\nThe primary outcome will be clinically significant rebound hyperbilirubinemia requiring repeat phototherapy within 24-48 hours after discontinuation of the initial phototherapy treatment. Secondary outcomes include rebound bilirubin levels, duration of hospitalization, and factors associated with repeat phototherapy.",[58,59],"Neonatal Hyperbilirubinemia","Rebound Hyperbilirubinemia",[59,61,62,63,64],"Neonatal Jaundice","Phototherapy","Neonate","Repeat Phototherapy","NOT_YET_RECRUITING","2026-07-09",{"date":68,"type":69},"2026-07-13","ACTUAL",{"date":71,"type":53},"2026-06-15",{"date":73,"type":53},"2026-11",{"name":5,"class":6},1]